Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 7/20 | 0.38 |
| ▸ | GAA | P10253 | 5/20 | 0.38 |
| ▸ | LMNA | P02545 | 3/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 8/20 | 0.35 |
| ▸ | MEN1 | O00255 | 7/20 | 0.35 |
| ▸ | NPSR1 | Q6W5P4 | 3/20 | 0.35 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.35 |
| ▸ | RECQL | P46063 | 1/20 | 0.35 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.34 |
| ▸ | NPC1 | O15118 | 2/20 | 0.34 |
| ▸ | RAB9A | P51151 | 2/20 | 0.34 |
| ▸ | POLB | P06746 | 2/20 | 0.33 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.33 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.33 |
| ▸ | HPGD | P15428 | 1/20 | 0.32 |
| ▸ | HTT | P42858 | 1/20 | 0.32 |
| ▸ | CRHBP | P24387 | 1/20 | 0.32 |
| ▸ | CRHR2 | Q13324 | 1/20 | 0.32 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.31 |
| ▸ | HPGDS | O60760 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Methane SCHEMBL9366272 | 0.86 | MAPT (0.42) | MAPTGAALMNAKMT2AMEN1 | |
| SCHEMBL9023452 | 0.85 | MAPT (0.44) | MAPTGAALMNAKMT2AMEN1 | |
| SCHEMBL9023457 | 0.85 | MAPT (0.44) | MAPTGAALMNAKMT2AMEN1 | |
| SCHEMBL9699589 | 0.85 | MAPT (0.44) | MAPTGAALMNAKMT2AMEN1 | |
| SCHEMBL10551133 | 0.85 | MAPT (0.39) | MAPTGAALMNAKMT2AMEN1 | |
| SCHEMBL10551124 | 0.85 | MAPT (0.39) | MAPTGAALMNAKMT2AMEN1 | |
| SCHEMBL8683544 | 0.84 | MAPT (0.44) | MAPTGAALMNAKMT2AMEN1 | |
| SCHEMBL8626419 | 0.84 | MAPT (0.44) | MAPTGAALMNAKMT2AMEN1 | |
| SCHEMBL10542977 | 0.84 | MAPT (0.44) | MAPTGAALMNAKMT2AMEN1 | |
| SCHEMBL2535653 | 0.83 | MAPT (0.38) | MAPTGAALMNACA12CA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20050209132-A1 | CROSS-LINKED GLYCOPEPTIDE-CEPHALOSPORIN ANTIBIOTICS | THERAVANCE BIOPHARMA ANTIBIOTICS IP, LLC | 2005-09-22 | — | — | US | disclosed |
| EP-1434779-A2 | CROSS-LINKED GLYCOPEPTIDE-CEPHALOSPORIN ANTIBIOTICS | Theravance, Inc. (US) | 2004-07-07 | — | — | EP | disclosed |
| WO-2003031449-A2 | CROSS-LINKED GLYCOPEPTIDE-CEPHALOSPORIN ANTIBIOTICS | THERAVANCE, INC. (US) | 2003-04-17 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050209132-A1 | CROSS-LINKED GLYCOPEPTIDE-CEPHALOSPORIN ANTIBIOTICS | CSGALNACT1, GYPA, ST3GAL3 | MAPT 4537/4885GAA 654/4885LMNA 3192/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.